Lecozotan

Summary

Lecozotan (CHEMBL372205) is a phase-3 clinical-stage small molecule; indicated across 1 condition including alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 483.6 Da · C28H29N5O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL372205
Name	Lecozotan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10116877
Molecular formula	C28H29N5O3
Molecular weight	483.6
InChIKey	NRPQELCNMADTOZ-OAQYLSRUSA-N

SMILES: C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5

IUPAC name: 4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide

Also known as: Lecozotan, LECOZOTAN

Parent form; salt/anhydrous children: CHEMBL2107349

Patent coverage: 72 distinct patent families (163 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	8.8	Ki	1.6	nM	CHEMBL_ACT_1506953
HTR1A	7.6	IC50	25	nM	CHEMBL_ACT_1506954
HTR1A	7.38	IC50	42	nM	CHEMBL_ACT_1506956

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	2	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00563732	PHASE1	COMPLETED	Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).